Hetero launches Favipiravir in India under the brand ‘Favivi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Hetero group has announced the launch of generic Favipiravir in India under the brand ‘Favivir’ for the treatment of mild to moderate Covid-19 following the approvals from the Drug Controller General of India (DCGI) to manufacture and market the generic drug.

This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in a hospital for treatment of severe Covid-19, under the license from Gilead Sciences.

Hetero said Favivir improves treatment accessibility to a significant amount of Covid-19 patient population, which usually sustains mild to moderate symptoms.

The company said the product was being made available at all retail medical outlets and hospital pharmacies across the country to be sold on prescription.

Further, the company said the drug is being manufactured at its world-class formulation facility, which was approved by the stringent global regulatory authorities such as the USFDA and the EU, among others, backed by strong vertical integration capabilities.

Source: https://health.economictimes.indiatimes.com/news/pharma/hetero-launches-favipiravir-in-india-under-the-brand-favivir-to-treat-covid-19/77237478
Dr. T●●●●z H●●●●●●i and 4 others like this4 shares
Like
Comment
Share